anti-CD3/anti-CLL-1 bispecific T-cell engager (Shanghai Taiyin Biotech)

N/A

Report date: 2026/03/19 16:57:15

Base Information

Drug Nameanti-CD3/anti-CLL-1 bispecific T-cell engager (Shanghai Taiyin Biotech)
Drug Alias Nameanti-CD3/anti-CLL-1 bispecific antibody (Shanghai Taiyin Biotech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Taiyin Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Taiyin Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A